Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.53) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.
Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.16). On average, analysts expect Elicio Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Elicio Therapeutics Stock Down 2.0%
Shares of ELTX opened at $2.89 on Thursday. The firm has a 50 day simple moving average of $6.44 and a two-hundred day simple moving average of $8.85. The company has a debt-to-equity ratio of 5.75, a current ratio of 2.24 and a quick ratio of 2.24. Elicio Therapeutics has a one year low of $2.66 and a one year high of $16.00. The company has a market cap of $55.17 million, a P/E ratio of -1.20 and a beta of 1.26.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on Elicio Therapeutics
Institutional Trading of Elicio Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its stake in shares of Elicio Therapeutics by 186.8% during the third quarter. Bank of America Corp DE now owns 3,585 shares of the company’s stock worth $39,000 after buying an additional 2,335 shares during the last quarter. Geode Capital Management LLC raised its position in Elicio Therapeutics by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 132,518 shares of the company’s stock valued at $1,055,000 after purchasing an additional 2,832 shares during the last quarter. Raymond James Financial Inc. bought a new position in Elicio Therapeutics in the second quarter valued at about $46,000. State Street Corp boosted its stake in shares of Elicio Therapeutics by 20.9% during the fourth quarter. State Street Corp now owns 46,300 shares of the company’s stock valued at $369,000 after purchasing an additional 8,000 shares in the last quarter. Finally, Summit Financial LLC acquired a new stake in shares of Elicio Therapeutics during the fourth quarter valued at about $80,000. Institutional investors and hedge funds own 35.03% of the company’s stock.
Elicio Therapeutics Company Profile
Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.
Featured Stories
- Five stocks we like better than Elicio Therapeutics
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Elicio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elicio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
